In a Swedish longitudinal prospective cohort of 132,402 subjects, SGLT2i users who showed dementia at baseline had a significantly lower dementia mortality rate (adjusted HR 0.43, 95%CI 0.23–0.80) compared to non-users, while insulin (adjusted HR 1.34, 95%CI 1.23–1.45, p < 0.001) or SUs (adjusted HR 1.19, 95%CI 1.01–1.42, p < 0.05) increased the mortality risk [118]. Here, INS is linked to dementia.